New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 6

Panel Discuses Use of CD19 Bispecifics in Sequencing

, , ,

Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.

Video content above is prompted by the following:

  • Is there a concern about targeting CD19 prior to administering CAR t-cell therapy?